Emtriva Related Published Studies
Well-designed clinical trials related to Emtriva (Emtricitabine)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. [2008.08.23]
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. [2008.03]
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. [2007.11.17]
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. [2007.08]
Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. [2007.07]
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. [2006.12.15]
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. [2006.05]
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. [2006.01.19]
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. [2005.09.01]
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. [2005.07]
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. [2005.03.15]
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. [2004.11.19]
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. [2004.11]
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. [2004.07.14]
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. [2003.12.01]
Well-designed clinical trials possibly related to Emtriva (Emtricitabine)
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. [2008.07]
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. [2007]
Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. [2006.06.15]
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. [2005.03.15]
Other research related to Emtriva (Emtricitabine)
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. [2008.10.01]
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. [2008.07]
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. [2008.07]
Addition of Single-Dose Tenofovir and Emtricitabine to Intrapartum Nevirapine to Reduce Perinatal HIV Transmission. [2008.06.01]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2008.05]
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. [2008.04.01]
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. [2008.04]
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. [2008.03.28]
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. [2008.02]
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. [2008.02]
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. [2008.01.02]
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis. [2008.01.01]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2007.12.31]
Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. [2007.10.01]
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. [2007.08]
Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen. [2007.07.19]
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. [2007.07.01]
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. [2007.06.19]
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. [2007.06]
Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137. [2007.03.29]
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? [2007.02]
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). [2007]
Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient. [2007]
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. [2006.12]
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. [2006.12]
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes: A 96-Week Analysis. [2006.10.12]
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. [2006.08]
Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking highly active antiretroviral therapy. [2006.07]
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. [2006.04]
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. [2006.01.09]
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. [2006.01.01]
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine. [2006]
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. [2006]
Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. [2005.04]
Emtricitabine: a review of its use in the management of HIV infection. [2005]
Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. [2004.07]
Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. [2004.06]
Emtricitabine (FTC) for the treatment of HIV infection. [2004.05]
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). [2004.03]
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. [2004.01]
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. [2004.01]
Intravenous lansoprazole: in erosive oesophagitis. [2004]
Reproductive toxicology profile of emtricitabine in mice and rabbits. [2003.01]
Emtricitabine: an antiretroviral agent for HIV infection. [2003]
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. [2002.06]
Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks. [2002.05]
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). [2001.10]
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. [2000.08]
Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. [2000.06]
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. [1999.09]
Other possibly related research studies
Drugs in development for hepatitis B. [2005]
Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. [2005.05]
Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). [2004.11]
[Recent progress in anti-HIM-1 research] [2004.06]
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. [2004.10]
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. [2004]
New treatment of chronic hepatitis B. [2004]
Initial therapy for human immunodeficiency virus: broadening the options. [2004.03]
Newer treatments for HIV in children. [2004.02]
Entecavir, FTC, L-FMAU, LdT and others. [2003]
Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. [2003.06]
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. [2002.06]
Hepatitis B infection in China. [2001.05]
Nucleoside analogues in the treatment of chronic hepatitis B. [2000.05]
In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients. [2005.10]
Gateways to clinical trials. [2005.10]
Gateways to clinical trials. [2005.07]
Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. [2005]
Managing hepatitis B coinfection in HIV-infected patients. [2005.08]
Gateways to clinical trials. [2005.06]
[New antiretroviral treatment modalities] [2005.06.04]
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. [2005.08.01]
Treatment of chronic hepatitis B. [2005.07]
Management of patients co-infected with hepatitis B virus and HIV. [2005.06]
[Treatment of chronic hepatitis B] [2005.03.31]
Current and future treatment of chronic hepatitis B. [2005.03]
Management of hepatitis B patients with antiviral resistance. [2004.12]
Interventions for managing antiretroviral therapy-associated lipoatrophy. [2005.02]
Gateways to clinical trials. [2004.10]
Pharmacokinetics of antiretrovirals in pregnant women. [2004]
Pharmacologic perspectives for once-daily antiretroviral therapy. [2004.11]
Gateways to clinical trials. [2004.06]
|
